You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The financing will support business expansion, continued technology development, and expenses related to a planned listing at the end of the year.
The Swedish molecular diagnostics firm will use the proceeds, in part, to fund the planned launch of its Immray PanCan-d assay for detecting pancreatic cancer.
The firm said it will use the funds to commercialize Colvera, its liquid biopsy test for earlier detection of recurrent colorectal cancer.
The financing will be used to hire additional team members and conduct additional studies in fertility science. The firm also launched its $199 fertility test.
The company entered a securities purchase agreement through which it has raised gross proceeds of $650,000 and paid down a portion of the company's debt.
The funding will help Mobidiag scale up production of its Novodiag instruments and disposable cartridges, and improve its global sales and marketing activities.
The financing round will support Grail's ongoing development and validation of early cancer detection products.
The financing will go toward further development of Klaris' phenotypic single-cell technology that can rapidly identify pathogens and determine their response to antibiotics.
Participants in the financing round included CS Investors, Pivotal Paramount Investment, and Stanford University.
The firm said that its technology enables the detection of rare DNA variants with high accuracy to enable liquid biopsy diagnosis and treatments for multiple diseases.